It warrants future clinical studies targeting the AhR‐dependent SRC/FAK/EGFR axis in combination with BRAFi/MEKi double blockade to re‐sensitize melanoma to standard melanoma treatment and counteract resistance. This evidence concerns the gene PTK2 and melanoma.